Study offers a combination treatment option for patients with oligometastatic prostate cancer
Can't see this email? View it online
   
  Prostate Cancer  
  The latest prostate cancer news from News Medical  
 Researchers identify new therapeutic approach against treatment-resistant prostate cancerResearchers identify new therapeutic approach against treatment-resistant prostate cancer
 
Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal Molecular Therapy, have led to a larger, multicenter trial that will soon be underway.
 
 
 Study offers a combination treatment option for patients with oligometastatic prostate cancerStudy offers a combination treatment option for patients with oligometastatic prostate cancer
 
A new study offers a new option to patients with oligometastatic prostate cancer who want relief from hormone therapy without compromising the risk of their disease spreading.
 
   Combination treatment improves progression-free survival in patients with oligometastatic prostate cancerCombination treatment improves progression-free survival in patients with oligometastatic prostate cancer
 
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer.
 
   More intensive prostate cancer screening may reduce the risk of metastatic cancer laterMore intensive prostate cancer screening may reduce the risk of metastatic cancer later
 
In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.
 
   Clinical trial confirms the safety, efficacy of shortened radiation therapy for high-risk prostate cancer patientsClinical trial confirms the safety, efficacy of shortened radiation therapy for high-risk prostate cancer patients
 
A new randomized study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy.
 
 $38,398 for a single shot of a very old cancer drug
 
$38,398 for a single shot of a very old cancer drugDr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn't been going out long when she laid down the law: He had to get a physical.
 
 
 Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer
 
Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancerFor patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) – focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT) – can slow the time to cancer progression, reports a study in The Journal of Urology, an Official Journal of the American Urological Association
 
 
 Polygenic hazard score could be effective for predicting genetic risk of lethal prostate cancer
 
Polygenic hazard score could be effective for predicting genetic risk of lethal prostate cancerTapping into the Million Veteran Program, an ongoing national research effort to learn how genes, lifestyle and military exposures affect the health of participants, researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.
 
 
 Research reveals molecular pathways of aggressive cribriform prostate cancer
 
Research reveals molecular pathways of aggressive cribriform prostate cancerCribriform prostate cancer is an aggressive subtype of the disease characterized by its histology, but little is known about its molecular pathways.